232 related articles for article (PubMed ID: 16292589)
1. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia.
de Haan L; Booij J; Lavalaye J; van Amelsvoort T; Linszen D
Psychopharmacology (Berl); 2006 Jan; 183(4):500-5. PubMed ID: 16292589
[TBL] [Abstract][Full Text] [Related]
2. Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications.
Frankle WG; Gil R; Hackett E; Mawlawi O; Zea-Ponce Y; Zhu Z; Kochan LD; Cangiano C; Slifstein M; Gorman JM; Laruelle M; Abi-Dargham A
Psychopharmacology (Berl); 2004 Oct; 175(4):473-80. PubMed ID: 15083259
[TBL] [Abstract][Full Text] [Related]
3. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia.
Lavalaye J; Linszen DH; Booij J; Reneman L; Gersons BP; van Royen EA
Psychiatry Res; 1999 Nov; 92(1):33-44. PubMed ID: 10688158
[TBL] [Abstract][Full Text] [Related]
4. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
[TBL] [Abstract][Full Text] [Related]
5. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
Kapur S; Zipursky RB; Remington G
Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.
Tsuboi T; Bies RR; Suzuki T; Mamo DC; Pollock BG; Graff-Guerrero A; Mimura M; Uchida H
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():178-82. PubMed ID: 23727135
[TBL] [Abstract][Full Text] [Related]
7. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
[TBL] [Abstract][Full Text] [Related]
8. Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine.
Schmitt GJ; Meisenzahl EM; Dresel S; Tatsch K; Rossmüller B; Frodl T; Preuss UW; Hahn K; Möller HJ
J Psychopharmacol; 2002 Sep; 16(3):200-6. PubMed ID: 12236625
[TBL] [Abstract][Full Text] [Related]
9. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
[TBL] [Abstract][Full Text] [Related]
10. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
[TBL] [Abstract][Full Text] [Related]
11. Frontal D2/3 Receptor Availability in Schizophrenia Patients Before and After Their First Antipsychotic Treatment: Relation to Cognitive Functions and Psychopathology.
Nørbak-Emig H; Ebdrup BH; Fagerlund B; Svarer C; Rasmussen H; Friberg L; Allerup PN; Rostrup E; Pinborg LH; Glenthøj BY
Int J Neuropsychopharmacol; 2016 May; 19(5):. PubMed ID: 26819282
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
14. Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia.
Paquet F; Soucy JP; Stip E; Lévesque M; Elie A; Bédard MA
J Neuropsychiatry Clin Neurosci; 2004; 16(1):47-56. PubMed ID: 14990759
[TBL] [Abstract][Full Text] [Related]
15. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
[TBL] [Abstract][Full Text] [Related]
16. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone.
de Haan L; Lavalaye J; Linszen D; Dingemans PM; Booij J
Am J Psychiatry; 2000 Jun; 157(6):1019-20. PubMed ID: 10831489
[TBL] [Abstract][Full Text] [Related]
17. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study.
Bigliani V; Mulligan RS; Acton PD; Ohlsen RI; Pike VW; Ell PJ; Gacinovic S; Kerwin RW; Pilowsky LS
Psychopharmacology (Berl); 2000 Jun; 150(2):132-40. PubMed ID: 10907666
[TBL] [Abstract][Full Text] [Related]
18. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
[TBL] [Abstract][Full Text] [Related]
19. Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study.
Bressan RA; Erlandsson K; Jones HM; Mulligan RS; Ell PJ; Pilowsky LS
J Clin Psychopharmacol; 2003 Feb; 23(1):5-14. PubMed ID: 12544369
[TBL] [Abstract][Full Text] [Related]
20. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.
Pilowsky LS; Busatto GF; Taylor M; Costa DC; Sharma T; Sigmundsson T; Ell PJ; Nohria V; Kerwin RW
Psychopharmacology (Berl); 1996 Mar; 124(1-2):148-53. PubMed ID: 8935810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
